HOME >> MEDICINE >> NEWS
Course of bipolar disorder in youths described for the first time

Children with bipolar disorder experience more enduring and rapidly changing symptoms of the disease than adults, according to a study that, for the first time, maps the clinical progression of each of the three sub-types of bipolar disorder in children and adolescents. The findings were published today by researchers from the University of Pittsburgh School of Medicine in the February issue of Archives of General Psychiatry. An estimated one out of 100 children and teenagers worldwide has bipolar disorder.

"Bipolar disorder is a serious illness that often emerges in adolescence, yet the majority of research into the disease has been done in adults. It became clear that we needed to define how bipolar disorder presents itself in this young, vulnerable population so we could take the next step of developing more age-specific treatments and therapies," said Boris Birmaher, M.D., professor of psychiatry at the University of Pittsburgh School of Medicine, and principal investigator and lead author of the study. "We found that the symptoms of bipolar disorder were longer lasting and more variable in youths than in adults. To have such symptoms at a young age deprives these children of the opportunity to experience normal emotional, cognitive and social development, establishing the urgent need to diagnose and treat these patients early on."

The study assessed the symptoms of 263 children and adolescents between the ages of 7 and 17 years who were diagnosed with bipolar spectrum disorders. Bipolar disorder, commonly called manic-depressive illness, is characterized by swings between depression, mania and periods with mixed symptoms. Bipolar spectrum disorders consist of three sub-types. Bipolar I (BP-I) is characterized by episodes of full-blown mania and major depression; bipolar II (BP-II) involves episodes of less severe mania, called hypomania, and major depression. The third sub-type, called bipolar not otherwise specified (BP-NOS), was defined in th
'"/>


6-Feb-2006


Page: 1 2 3

Related medicine news :

1. Advances in understanding bipolar disorder topics of press briefings June 7, 8
2. Study sheds light on medication treatment options for bipolar disorder
3. UIC receives grant to find new drugs for bipolar disorder
4. New gene linked to bipolar disorder
5. Short episodes of manic symptoms may indicate bipolar disorder in some youth
6. New treatment model for bipolar disorder shows promise
7. Study identifies predictors of bipolar disorder risk
8. Yale findings hold promise for stopping progression of bipolar disorder
9. New book on bipolar disorder targets 12 million affected Americans, families
10. Emotional impairment linked to cognitive deficits in bipolar children
11. BOLDER II study confirms therapeutic potential of SEROQUEL in bipolar depression

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Course bipolar disorder youths described for the first time

(Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
(Date:11/22/2014)... Setria® Glutathione is now available ... for use “as a therapeutically active ingredient in ... Therapeutic Goods (Listing) Notice 2014 (No. 5) - ... Glutathione will be exclusivity distributed in Australia by ... imports fine chemicals to Australian manufacturers. TGA approval ...
(Date:11/22/2014)... Discount-Dress.com is an important company in the dress industry. ... company’s online market share by a series of promotions. Recently, ... announced a bridesmaid dress promotion for the new year 2015. ... the dresses from this company are not only of high ... very good at manufacturing wedding dresses. Customers prefer to choose ...
(Date:11/22/2014)... November 22, 2014 Nocturia is ... the complaint that the individual has to wake ... The report “Nocturia – Pipeline Review, H2 2014” ... Nocturia, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:11/22/2014)... 22, 2014 A petition seeking a ... ) in minimally-invasive hysterectomies and fibroid removal surgeries ... end of October, Bernstein Liebhard LLP reports. According ... of November 21st, 2014. That represents an increase of ... signed on to the campaign.* , The campaign to ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
(Date:11/21/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... to acquire 100% of QCR & Trio Diagnostics Limited, ... organization. The transaction closed on November 17, 2014. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
Cached News: